WO2005120456A3 - Formulation of eletriptan - Google Patents

Formulation of eletriptan Download PDF

Info

Publication number
WO2005120456A3
WO2005120456A3 PCT/IB2005/001828 IB2005001828W WO2005120456A3 WO 2005120456 A3 WO2005120456 A3 WO 2005120456A3 IB 2005001828 W IB2005001828 W IB 2005001828W WO 2005120456 A3 WO2005120456 A3 WO 2005120456A3
Authority
WO
WIPO (PCT)
Prior art keywords
eletriptan
formulation
solvate
encapsulation
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2005/001828
Other languages
French (fr)
Other versions
WO2005120456A2 (en
Inventor
Hassan Benameur
Michael Paul Fitzgerald
Original Assignee
Pfizer Ltd
Pfizer
Hassan Benameur
Michael Paul Fitzgerald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412882A external-priority patent/GB0412882D0/en
Application filed by Pfizer Ltd, Pfizer, Hassan Benameur, Michael Paul Fitzgerald filed Critical Pfizer Ltd
Publication of WO2005120456A2 publication Critical patent/WO2005120456A2/en
Publication of WO2005120456A3 publication Critical patent/WO2005120456A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Colloid Chemistry (AREA)

Abstract

The present invention relates to a water-in-oil microemulsion, suitable for encapsulation, comprising eletriptan, or a pharmaceutically acceptable salt or solvate thereof.
PCT/IB2005/001828 2004-06-09 2005-05-30 Formulation of eletriptan WO2005120456A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0412882A GB0412882D0 (en) 2004-06-09 2004-06-09 New formulation of eletriptan
GB0412882.3 2004-06-09
US58179604P 2004-06-22 2004-06-22
US60/581,796 2004-06-22

Publications (2)

Publication Number Publication Date
WO2005120456A2 WO2005120456A2 (en) 2005-12-22
WO2005120456A3 true WO2005120456A3 (en) 2006-09-21

Family

ID=35355052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001828 WO2005120456A2 (en) 2004-06-09 2005-05-30 Formulation of eletriptan

Country Status (1)

Country Link
WO (1) WO2005120456A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1970051A1 (en) * 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases
WO2009077858A2 (en) * 2007-12-17 2009-06-25 Actavis Group Ptc Ehf Novel hemioxalate salt of eletriptan
EP2374448A1 (en) * 2010-04-06 2011-10-12 Labtec GmbH Oral film formulation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758263A1 (en) * 1997-01-16 1998-07-17 Oreal USE OF AN ANTAGONIST OR AN AGONIST OF SEROTONIN RESPECTIVELY OF THE RECEPTOR 5HT2 AND 5HT1D IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKIN AND COMPOSITION OBTAINED
WO2002009675A1 (en) * 2000-08-02 2002-02-07 Pfizer Limited Particulate composition of eletriptan showing a sigmoidal pattern of controlled release
US20020165120A1 (en) * 2001-03-01 2002-11-07 Pfizer Inc. Compositions having improved bioavailability

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758263A1 (en) * 1997-01-16 1998-07-17 Oreal USE OF AN ANTAGONIST OR AN AGONIST OF SEROTONIN RESPECTIVELY OF THE RECEPTOR 5HT2 AND 5HT1D IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKIN AND COMPOSITION OBTAINED
WO2002009675A1 (en) * 2000-08-02 2002-02-07 Pfizer Limited Particulate composition of eletriptan showing a sigmoidal pattern of controlled release
US20020165120A1 (en) * 2001-03-01 2002-11-07 Pfizer Inc. Compositions having improved bioavailability

Also Published As

Publication number Publication date
WO2005120456A2 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
EP1650192A4 (en) Quinolone derivative or salt thereof
EP1740156B8 (en) Method for the production of an abuse-proof, solid form of administration
WO2007146248A3 (en) Stable laquinimod preparations
WO2006039164A3 (en) Novel cyclosporin analogues and their pharmaceutical uses
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
ZA200702382B (en) Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines
WO2006068826A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2006120552A3 (en) ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE
IL175953A (en) 3-cycloalkylaminopyrrolidine derivatives, pharmaceutically acceptable salts thereof and compositions comprising the same
WO2006039163A3 (en) Cyclosporin alkyne analogues and their pharmaceutical uses
EP1704856A4 (en) Hsp90 family protein inhibitor
WO2006012385A3 (en) Crystalline mycophenolate sodium
WO2007016352A3 (en) Oral liquid losartan compositions
WO2006081515A3 (en) Duloxetine hydrochloride polymorphs
HK1101587A1 (en) Method for the preparation of d-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative
WO2004105773A3 (en) Use of s1p
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
WO2005033113A3 (en) Indole derivatives
CA2489140A1 (en) Dosage form containing pantoprazole as active ingredient
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
WO2007007182A3 (en) Solid and liquid dosage forms of an antiepileptic agent
WO2007144699A3 (en) Process for the preparation of alfuzosin
EP1617847A4 (en) Methods for the controlled delivery of pharmacologically active compounds
WO2006002073A3 (en) Method for preventing heme-induced lipid peroxidation
WO2005120456A3 (en) Formulation of eletriptan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase